X

Trial Profile

A Phase Ib, Multiple Ascending Dose Study to Evaluate CDX-0159 in Patients with Chronic Idiopathic Urticaria

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Barzolvolimab (Primary)
Indications Urticaria
Focus Proof of concept; Therapeutic Use
Sponsors Celldex Therapeutics Inc

Most Recent Events

06 Aug 2020 According to a Celldex Therapeutics media release, data from this study is expected first quarter of 2021.
06 Jun 2020 According to a Celldex Therapeutics media release, data from this study is expected early next year.
26 Mar 2020 According to a Celldex Therapeutics media release, this study is expected to be initiated by end of 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com